DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities reissued a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Trading Up 10.0 %

Shares of DBVT stock opened at $6.82 on Friday. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $8.32. The business’s 50 day moving average is $4.49 and its two-hundred day moving average is $3.88. The company has a market capitalization of $140.28 million, a P/E ratio of -1.52 and a beta of 0.71.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent reporting period. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.